查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1998365

癌症和腫瘤分析市場：按技術、產品類型、應用和最終用戶分類－2026-2032年全球市場預測

Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症和腫瘤分析市場價值將達到 152.9 億美元，到 2026 年將成長到 183.1 億美元，到 2032 年將達到 545.5 億美元，複合年成長率為 19.92%。

主要市場統計數據
基準年 2025 152.9億美元
預計年份：2026年 183.1億美元
預測年份 2032 545.5億美元
複合年成長率 (%) 19.92%

對腫瘤分析進行策略概述，提出技術整合、臨床效用和相關人員的獎勵，以指導經營團隊決策。

本執行摘要整合了技術進步、監管環境、臨床效用和商業策略，全面展現了腫瘤譜分析整體情況不斷發展的觀點。其目標是為高階主管、臨床負責人、研發經理和策略投資者提供清晰且可操作的概要，闡明影響腫瘤診斷和轉化醫學優先事項的關鍵因素。透過整合跨學科趨勢和實際應用，本文檔旨在簡化複雜性，並為短期決策提供一致的基礎。

對改變腫瘤分析的根本變化進行全面分析，包括技術融合、監管協調和整合的臨床工作流程。

在腫瘤分析領域，一系列變革正在發生，其驅動力包括技術成熟、臨床路徑轉變以及對個人化醫療日益成長的關注。定序能力和準確性的提升降低了技術門檻，使得複雜的診斷方法能夠在學術和社區醫療機構中廣泛應用。同時，生物資訊流程和雲端平台的進步正在從多模態數據中提取具有臨床應用價值的信息，從而重塑診斷流程和治療決策。

詳細檢視美國近期關稅措施如何重塑腫瘤分析領域的供應鏈、籌資策略和臨床應用。

美國新關稅的實施為腫瘤分析生態系統中的相關人員帶來了營運和策略方面的考量，影響供應鏈的採購、定價和供應商選擇。進口設備和試劑的關稅可能會影響採購計劃，並促使本地生產和供應商多元化。因此，臨床檢查室和醫院正在重新審視供應商協議和庫存策略，以應對成本波動，同時確保患者檢測的連續性。

全面的細分洞察揭示了技術類別、產品類型、臨床應用和最終用戶如何以獨特的方式影響診斷策略和部署。

對腫瘤譜分析領域進行細緻的細分，可以揭示創新和應用壓力最為顯著的領域，這些細分可按技術、產品類型、應用和最終用戶分類。從技術角度來看，該領域包括常規PCR、數位PCR、FISH、IHC、微陣列、次世代定序和即時PCR ，每種技術都具有其獨特的分析優勢和操作特性。在FISH中，染色體計數探針、拷貝數變異和融合基因檢測仍然是評估細胞遺傳學和結構變異的核心。同時，IHC技術，例如直接IHC、間接IHC和組織微陣列，仍是組織病理學工作流程中蛋白質表現和受體譜分析的基礎。儘管定序取代了一些傳統應用，但微陣列技術，包括比較基因組雜合反應、表現譜分析和SNP基因型鑒定，仍在特定的研究和診斷領域中發揮作用。

區域觀點凸顯了全球主要市場在部署模式、監管趨勢和基礎設施優先事項方面的差異。

在腫瘤譜分析領域，區域趨勢顯著影響技術應用、報銷模式和合作研究舉措。在美洲，對精準腫瘤學基礎設施的投資以及私人實驗室與醫院系統之間的密切合作，正在加速高通量定序和液態生物檢體應用的普及。該地區的臨床和商業生態系統優先考慮快速檢驗週期，並與製藥公司建立合作關係，以支持生物標記主導的臨床試驗和伴隨診斷的開發，同時也強調與支付方（保險公司）合作，以證明其臨床效用。

市場資訊顯示，主要製造商、試劑專家和軟體創新公司正在腫瘤分析領域建立合作夥伴關係並重建競爭優勢。

在儀器、耗材和軟體生態系統中，主要企業扮演著不同的角色，它們的策略選擇塑造了腫瘤分析領域的競爭動態和客戶期望。成熟的定序平台供應商持續投資於通量、準確性和工作流程自動化，以支援臨床級檢測。同時，試劑和耗材專家則專注於檢測檢驗、批間一致性和供應連續性。規模較小的小規模公司則透過細分應用、檢測專業化以及能夠簡化結果解讀和報告的整合軟體來脫穎而出。

為領導者提供具體建議，以加強韌性、證據生成、互通性和經營模式，從而推動永續採用。

產業領導者應優先考慮一系列切實可行的優先事項，旨在增強韌性、加速臨床部署並最大化商業性回報。首先，應優先考慮整合解決方案，將經過檢驗的儀器、穩定的試劑供應和強大的分析軟體結合，因為客戶越來越重視能夠降低營運複雜性和監管負擔的供應商。其次，應投資於符合支付方要求和臨床終點的實證策略，因為真實世界結果和前瞻性臨床檢驗仍然是報銷和指南採納的關鍵因素。第三，應制定靈活的供應鏈策略，包括區域生產、策略夥伴關係和庫存管理技術，以降低關稅和地緣政治風險。

穩健的調查方法，結合系統性的文獻回顧、專家訪談和交叉檢驗證據的整合，為可操作的見解奠定了基礎。

本次高階主管分析的調查方法結合了定性和定量證據、對關鍵相關人員的訪談以及領域專家的結構化檢驗。此方法首先對同儕審查文獻、監管指導文件和臨床實踐標準進行系統性回顧，以確定技術能力、檢驗要求和臨床效用框架。桌上研究，也對實驗室主任、腫瘤學家、生物資訊經理、採購專家和銷售主管進行了有針對性的訪談，以了解實施的實際情況和策略重點。

簡潔的結論整合了合作的必要性、證據的一致性以及實現精準腫瘤學益處的穩健策略。

總之，腫瘤分析正從單一的檢查室檢測轉向整合式診斷生態系統，該系統結合了先進的分析技術、可擴展的工作流程和基於證據的商業化策略。定序、數位檢測和生物資訊學的技術進步正在拓展其臨床應用，使其涵蓋從診斷到監測和治療方法選擇的各個方面。同時，監管機構和保險公司日益嚴格的監督推動了更嚴謹證據的產生和協作檢驗模型的發展。因此，供應商、臨床檢查室和生命科學合作夥伴必須在互通性、品質標準和真實世界臨床結果方面達成一致，才能充分發揮精準腫瘤學的潛力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症和腫瘤分析市場：按技術分類

  • 常規PCR
  • 數位PCR
  • FISH
    • 染色體計數探針
    • 拷貝編號變體
    • 融合基因檢測
  • IHC
    • 直接免疫組化
    • 間接免疫組化
    • 組織微陣列
  • 微陣列
    • 比較基因雜合反應
    • 表達譜分析
    • SNP基因基因型鑒定
  • 次世代定序
    • 目標序列
      • 擴增子法
      • 混合捕獲
    • 轉錄組序列
    • 全EXOME定序
    • 全基因組定序
  • 即時PCR
    • 顏料基底
    • 探針法

第9章 癌症和腫瘤分析市場：按產品類型分類

  • 耗材和試劑
    • 抗體
    • PCR試劑
    • 探測
    • 定序試劑
  • 裝置
    • 螢光顯微鏡
    • 質譜儀
    • 微陣列掃描儀
    • PCR裝置
    • 序列器
  • 軟體服務
    • 生物資訊軟體
    • 雲端平台
    • 諮詢服務
    • 資料管理系統

第10章 癌症和腫瘤分析市場：按應用領域分類

  • 乳癌
    • 基因表現分析
    • 基因突變檢測
    • 蛋白質體學分析
    • 受體譜分析
  • 結腸癌
    • 表觀遺傳譜分析
    • MSI 測試
    • 突變分析
  • 肺癌
    • 微量殘存疾病的監測
    • 分子敏感性測試
    • 治療方法方案
  • 攝護腺癌
    • 拷貝數變異分析
    • 融合基因檢測
    • 基因表現分析

第11章 癌症和腫瘤分析市場：按最終用戶分類

  • 診斷檢查室
    • 臨床檢查室
    • 參考檢測實驗室
  • 醫院和診所
    • 腫瘤學
    • 病理檢查室
  • 製藥和生物製藥公司
    • 臨床試驗部門
    • 伴隨診斷服務
    • 藥物開發部
  • 研究機構和學術機構
    • 生物技術研究中心
    • 政府附屬研究機構
    • 大學研究實驗室

第12章 癌症和腫瘤分析市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 癌症與腫瘤分析市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 癌症和腫瘤分析市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國癌症與腫瘤分析市場

第16章：中國癌症與腫瘤分析市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Caris Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Sysmex Corporation
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-374DB5A06C7F

The Cancer/Tumor Profiling Market was valued at USD 15.29 billion in 2025 and is projected to grow to USD 18.31 billion in 2026, with a CAGR of 19.92%, reaching USD 54.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.29 billion
Estimated Year [2026] USD 18.31 billion
Forecast Year [2032] USD 54.55 billion
CAGR (%) 19.92%

Strategic introduction to tumor profiling that frames technological convergence, clinical utility, and stakeholder incentives to guide executive decision-making

This executive summary introduces a comprehensive perspective on the evolving tumor profiling landscape, synthesizing technological advances, regulatory dynamics, clinical utility, and commercial strategies. The purpose is to equip senior executives, clinical leaders, R&D heads, and strategic investors with a clear and actionable synthesis of the forces shaping diagnostic and translational oncology priorities. By consolidating cross-disciplinary trends and pragmatic implications, the document aims to reduce complexity and provide a coherent foundation for near-term decision making.

The introduction frames tumor profiling not merely as a set of laboratory techniques but as a convergent ecosystem where genomics, proteomics, and informatics intersect with clinical workflows. It highlights how assay selection, data management, and end-user integration collectively determine the clinical value chain. Moreover, the narrative clarifies stakeholder incentives-from payers and hospital systems to pharma partners and academic centers-thereby establishing the context for subsequent sections that examine market shifts, policy influences, segmentation drivers, and regional nuances.

Finally, the introduction outlines the analytical approach used across the report, emphasizing evidence synthesis, expert triangulation, and a focus on practical implications rather than purely academic reviews. This orientation ensures readers can rapidly translate insights into prioritized actions, whether optimizing procurement strategies, refining product roadmaps, or aligning clinical validation programs with emerging standards.

Comprehensive analysis of fundamental shifts transforming tumor profiling including technology convergence, regulatory alignment, and integrated clinical workflows

The tumor profiling landscape is experiencing a set of transformative shifts driven by technological maturation, changing clinical pathways, and a heightened emphasis on personalized medicine. Advances in sequencing throughput and precision are reducing technical barriers and enabling broader adoption of complex assays in both academic and community settings. At the same time, improvements in bioinformatics pipelines and cloud-based platforms are unlocking clinically actionable insights from multimodal data, which in turn is reshaping diagnostic workflows and therapeutic decision points.

Concurrently, payers and regulators are increasingly focused on demonstrating clinical utility and ensuring analytical validity, which is prompting companies to align evidence generation with real-world clinical endpoints. This regulatory emphasis is accelerating partnerships between diagnostics companies, clinical laboratories, and pharmaceutical sponsors to co-develop companion diagnostics and generate outcomes-based evidence. Furthermore, the integration of liquid biopsy approaches and minimal residual disease monitoring into routine care pathways is expanding the clinical use cases for tumor profiling beyond initial diagnosis to surveillance and therapy selection.

In addition, supply chain resilience and platform consolidation are influencing procurement behavior among hospitals, reference laboratories, and research centers. These structural shifts favor integrated solutions that combine instruments, validated consumables, and robust software ecosystems. As a result, vendors that can demonstrate end-to-end value, interoperability, and scalable service models are gaining a competitive edge. In summary, the landscape is moving from isolated assays toward integrated diagnostic strategies that support adaptive clinical management and collaborative evidence generation.

In-depth examination of how recent United States tariff measures are reshaping supply chains, procurement strategies, and clinical deployment across tumor profiling

The imposition of new tariff measures in the United States has introduced operational and strategic considerations for stakeholders across the tumor profiling ecosystem, affecting supply chain sourcing, procurement pricing, and vendor selection. Tariffs on imported instruments and reagents can influence procurement timetables and create incentives for localized manufacturing or supplier diversification. As a result, clinical laboratories and hospitals are reassessing vendor contracts and inventory strategies to buffer against cost volatility while maintaining continuity of patient testing.

Moreover, tariff-driven adjustments are prompting manufacturers and distributors to reconsider their commercial models. Some vendors are exploring regional production hubs, strategic partnerships with domestic suppliers, and vertically integrated supply chains to mitigate exposure. This shift often involves re-evaluating product portfolios, prioritizing high-margin consumables for localized production, and optimizing logistics to minimize landed cost impacts. In parallel, service-oriented offerings and software subscriptions are being emphasized as ways to preserve revenue stability amid hardware pricing pressures.

From a clinical perspective, the indirect consequences of tariffs-such as delayed instrument deployments or constrained reagent availability-can affect study timelines, trial enrollment, and the rollout of new assays. Therefore, stakeholders are increasingly incorporating supply chain risk assessments into clinical program planning and procurement governance. In short, tariffs have catalyzed a broader reassessment of resilience and localization strategies across the tumor profiling value chain, encouraging collaborative approaches between manufacturers, distributors, and end users to sustain innovation and patient access.

Comprehensive segmentation insight revealing how technology categories, product types, clinical applications, and end users uniquely shape diagnostic strategies and adoption

A careful segmentation of the tumor profiling domain illuminates where innovation and adoption pressures are most pronounced across technology, product type, application, and end user. Based on technology, the field encompasses Conventional PCR, Digital PCR, FISH, IHC, Microarray, Next Generation Sequencing, and Real Time PCR, each offering distinct analytical strengths and operational footprints. Within FISH, chromosome enumeration probes, copy number variation, and fusion gene detection remain central to cytogenetic and structural variant assessments, while IHC modalities such as direct IHC, indirect IHC, and tissue microarray continue to underpin protein expression and receptor profiling in histopathology workflows. Microarray approaches, including comparative genomic hybridization, expression profiling, and SNP genotyping, still play roles in certain research and diagnostic niches even as sequencing displaces some legacy applications.

Next Generation Sequencing is itself stratified across targeted sequencing, transcriptome sequencing, whole exome sequencing, and whole genome sequencing, reflecting a tiered approach to depth, breadth, and clinical applicability. Targeted sequencing further divides into amplicon-based and hybrid capture methods, which differ in input requirements, sensitivity, and design flexibility. Real Time PCR remains a workhorse for quantitation and rapid assays, split between dye-based and probe-based chemistries that trade off cost, multiplexing capability, and specificity.

Turning to product type, the market is delineated into consumables and reagents, instruments, and software and services. Consumables and reagents-encompassing antibodies, PCR reagents, probes, and sequencing reagents-drive recurring revenue and are tightly coupled to platform adoption. Instruments, from fluorescence microscopes and mass spectrometers to microarray scanners, PCR instruments, and sequencers, represent capital investments that influence laboratory capability and throughput. Software and services, including bioinformatics software, cloud platforms, consultation services, and data management systems, are increasingly decisive in value propositions because they enable interpretation, regulatory compliance, and seamless integration with clinical workflows.

Applications span breast cancer, colorectal cancer, lung cancer, and prostate cancer, with each indication demanding tailored assay portfolios and validation strategies. Breast cancer programs commonly emphasize gene expression profiling, genetic mutation detection, proteomic profiling, and receptor profiling to inform treatment choice and prognosis. Colorectal cancer programs rely on epigenetic profiling, microsatellite instability testing, and mutation analysis to inform screening and therapeutic decisions. Lung cancer profiling prioritizes minimal residual disease monitoring, molecular susceptibility testing, and therapy selection to guide targeted therapies and monitoring strategies. Prostate cancer workflows employ copy number variation analysis, fusion detection, and gene expression analysis to refine risk stratification and management pathways.

Finally, the end-user segmentation highlights the diverse settings where tumor profiling is deployed, including diagnostic laboratories, hospitals and clinics, pharma and biopharma companies, and research and academic institutes. Diagnostic laboratories, whether clinical or reference, focus on throughput, cost per test, and standardized workflows. Hospitals and clinics balance on-site diagnostics with centralized laboratory partnerships and place a premium on turnaround time and clinical integration. Pharma and biopharma entities, spanning clinical trial units, companion diagnostic services, and drug development divisions, seek scalable, validated assays that support trial endpoints and regulatory submissions. Research and academic institutes, including biotech research centers, government research institutes, and university research labs, emphasize methodological flexibility, exploratory assays, and collaboration with clinical partners. Collectively, these segmentation lenses reveal differentiated demand drivers, investment priorities, and commercialization pathways across the tumor profiling ecosystem.

Nuanced regional perspective highlighting divergent adoption patterns, regulatory dynamics, and infrastructure priorities across major global markets

Regional dynamics exert a major influence on technology adoption, reimbursement models, and collaborative research initiatives within the tumor profiling landscape. In the Americas, investment in precision oncology infrastructure and strong integration between commercial laboratories and hospital systems have accelerated the adoption of high-throughput sequencing and liquid biopsy applications. This region's clinical and commercial ecosystems prioritize rapid validation cycles and partnerships with pharmaceutical sponsors to support biomarker-driven trials and companion diagnostic development, while also emphasizing payer engagement to demonstrate clinical utility.

Meanwhile, Europe, the Middle East & Africa presents a heterogeneous environment where regulatory frameworks, national health priorities, and laboratory capacities vary significantly. European regulatory harmonization efforts and centralized health technology assessment processes shape reimbursement pathways and clinical adoption, whereas markets in the Middle East and Africa may prioritize capacity building and technology transfer to expand diagnostic coverage. Across this region, academic consortia and pan-national collaborations are playing important roles in standardizing assay validation and enabling cross-border research efforts.

In the Asia-Pacific region, rapid investments in genomic infrastructure, expanding clinical trial activity, and an increasing emphasis on domestically produced diagnostics are driving distinct adoption patterns. Many countries in this region are advancing national genomics initiatives and fostering public-private partnerships to scale molecular diagnostics. Consequently, vendors are adapting commercial strategies to accommodate local regulatory requirements, pricing expectations, and capacity-building programs. Taken together, these regional insights underscore the need for geographically differentiated go-to-market strategies, evidence plans tailored to local stakeholders, and operational models that address region-specific supply chain and regulatory realities.

Market intelligence on how leading manufacturers, reagent specialists, and software innovators are forming partnerships and reshaping competitive advantage in tumor profiling

Leading companies play distinct roles across instruments, consumables, and software ecosystems, and their strategic choices are shaping competitive dynamics and customer expectations within tumor profiling. Established sequencing platform providers continue to invest in throughput, accuracy, and workflow automation to support clinical-grade assays, while reagent and consumable specialists focus on assay validation, lot-to-lot consistency, and supply continuity. At the same time, smaller innovators are differentiating through niche applications, assay specialization, and integrated software that streamlines interpretation and reporting.

Partnerships between diagnostics firms and pharmaceutical companies remain a central tactic to accelerate companion diagnostic development and co-generated clinical evidence. These collaborations frequently involve joint assay validation, shared data platforms, and coordinated regulatory filings to reduce time to clinic. Additionally, several instrument manufacturers are expanding their service portfolios to include training, maintenance, and remote monitoring to reduce operational barriers for clinical laboratories and hospital networks. Software vendors that deliver scalable bioinformatics, secure cloud platforms, and regulatory-ready data management systems are increasingly influential because they bridge raw data generation with clinical decision support.

Competitive advantage is therefore driven by an ability to offer validated, interoperable solutions that integrate hardware, consumables, and interpretation services. Companies that can demonstrate rigorous clinical validation, robust supply chains, and a clear pathway for regulatory compliance are better positioned to win long-term contracts with reference labs, hospital systems, and pharma partners. In this context, the ecosystem is shifting toward collaborative models where innovation is co-created across vendors, clinical institutions, and life sciences partners to accelerate adoption and maintain clinical relevance.

Actionable recommendations for leaders to strengthen resilience, evidence generation, interoperability, and commercial models that drive sustained adoption

Industry leaders should pursue a set of actionable priorities designed to strengthen resilience, accelerate clinical adoption, and maximize commercial returns. First, prioritize integrated solutions that combine validated instruments, consistent reagent supplies, and robust interpretive software, because customers increasingly reward vendors that reduce operational complexity and regulatory burden. Second, invest in evidence generation strategies that align with payer requirements and clinical endpoints, as real-world outcomes and prospective clinical validation remain decisive for reimbursement and guideline inclusion. Third, develop flexible supply chain strategies that include regional production, strategic partnerships, and inventory management practices to mitigate tariff-driven and geopolitical risks.

Furthermore, create value-based contracting and performance guarantees that align commercial terms with demonstrated clinical outcomes, which will help bridge payer skepticism and support broader access. Emphasize interoperability and standards-based data exchange to facilitate integration into electronic health records and tumor boards, thereby increasing clinician uptake. Additionally, cultivate collaborative partnerships with academic centers and pharma sponsors to co-develop assays, which accelerates validation and expands clinical use cases. Finally, build modular service offerings and scalable support models-ranging from training and maintenance to bioinformatics subscription services-to create recurring revenue streams and deepen customer relationships.

By executing these priorities, organizations can not only navigate near-term disruptions but also position themselves to capture long-term value as tumor profiling becomes more embedded in personalized oncology pathways. In doing so, leaders should remain adaptive, monitor policy and reimbursement shifts, and continuously translate clinical feedback into product and service improvements.

Robust research methodology combining systematic literature review, expert interviews, and cross-validated evidence synthesis to underpin actionable insights

The research methodology underpinning this executive analysis combines qualitative and quantitative evidence synthesis, primary stakeholder interviews, and structured validation with subject matter experts. The approach began with a systematic review of peer-reviewed literature, regulatory guidance documents, and clinical practice standards to identify technological capabilities, validation requirements, and clinical utility frameworks. This desk research was complemented by targeted interviews with laboratory directors, oncologists, bioinformatics leaders, procurement specialists, and commercial executives to capture implementation realities and strategic priorities.

Secondary validation included cross-referencing vendor technical specifications, publicly available regulatory filings, and clinical trial registries to ensure the analytical narrative aligned with current product capabilities and evidence generation pathways. Triangulation techniques were applied to reconcile differences between commercial positioning and clinical practice, with particular attention to workflow integration, turnaround time constraints, and data governance needs. Where applicable, case studies and anonymized examples were used to illustrate practical implications without disclosing proprietary details.

Finally, the methodology incorporated scenario analysis to explore how policy shifts, supply chain disruptions, and technological inflection points might influence stakeholder behavior. Throughout the process, emphasis was placed on transparency of assumptions, reproducibility of sources, and the translation of technical detail into operational recommendations suitable for executive decision-making.

Concise conclusion that synthesizes the imperative for collaboration, evidence alignment, and resilient strategies to realize precision oncology benefits

In conclusion, tumor profiling is transitioning from discrete laboratory assays to integrated diagnostic ecosystems that combine advanced analytics, scalable workflows, and evidence-aligned commercialization strategies. Technological advances in sequencing, digital assays, and bioinformatics are expanding clinical applications from diagnosis to monitoring and therapy selection, while regulatory and payer scrutiny is encouraging more rigorous evidence generation and collaborative validation models. Consequently, vendors, clinical laboratories, and life sciences partners must align on interoperability, quality standards, and real-world outcomes to realize the promise of precision oncology.

The cumulative effect of supply chain pressures and policy changes underscores the importance of resilient procurement strategies and localized manufacturing where appropriate. Moreover, regional variations in adoption and regulatory frameworks require tailored market approaches that reflect local clinical priorities and infrastructure capabilities. Companies that can offer validated, end-to-end solutions and demonstrate clear clinical benefit are positioned to lead the next phase of adoption.

Overall, the path forward depends on sustained collaboration between diagnostics providers, clinical stakeholders, and research institutions to translate technological capability into measurable patient impact. By focusing on evidence, operational integration, and strategic partnerships, organizations can accelerate meaningful improvements in cancer diagnosis and management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer/Tumor Profiling Market, by Technology

  • 8.1. Conventional PCR
  • 8.2. Digital PCR
  • 8.3. FISH
    • 8.3.1. Chromosome Enumeration Probes
    • 8.3.2. Copy Number Variation
    • 8.3.3. Fusion Gene Detection
  • 8.4. IHC
    • 8.4.1. Direct IHC
    • 8.4.2. Indirect IHC
    • 8.4.3. Tissue Microarray
  • 8.5. Microarray
    • 8.5.1. Comparative Genomic Hybridization
    • 8.5.2. Expression Profiling
    • 8.5.3. SNP Genotyping
  • 8.6. Next Generation Sequencing
    • 8.6.1. Targeted Sequencing
      • 8.6.1.1. Amplicon Based
      • 8.6.1.2. Hybrid Capture
    • 8.6.2. Transcriptome Sequencing
    • 8.6.3. Whole Exome Sequencing
    • 8.6.4. Whole Genome Sequencing
  • 8.7. Real Time PCR
    • 8.7.1. Dye Based
    • 8.7.2. Probe Based

9. Cancer/Tumor Profiling Market, by Product Type

  • 9.1. Consumables Reagents
    • 9.1.1. Antibodies
    • 9.1.2. PCR Reagents
    • 9.1.3. Probes
    • 9.1.4. Sequencing Reagents
  • 9.2. Instruments
    • 9.2.1. Fluorescence Microscopes
    • 9.2.2. Mass Spectrometers
    • 9.2.3. Microarray Scanners
    • 9.2.4. PCR Instruments
    • 9.2.5. Sequencers
  • 9.3. Software & Services
    • 9.3.1. Bioinformatics Software
    • 9.3.2. Cloud Platforms
    • 9.3.3. Consultation Services
    • 9.3.4. Data Management Systems

10. Cancer/Tumor Profiling Market, by Application

  • 10.1. Breast Cancer
    • 10.1.1. Gene Expression Profiling
    • 10.1.2. Genetic Mutation Detection
    • 10.1.3. Proteomic Profiling
    • 10.1.4. Receptor Profiling
  • 10.2. Colorectal Cancer
    • 10.2.1. Epigenetic Profiling
    • 10.2.2. MSI Testing
    • 10.2.3. Mutation Analysis
  • 10.3. Lung Cancer
    • 10.3.1. Minimal Residual Disease Monitoring
    • 10.3.2. Molecular Susceptibility Testing
    • 10.3.3. Therapy Selection
  • 10.4. Prostate Cancer
    • 10.4.1. Copy Number Variation Analysis
    • 10.4.2. Fusion Detection
    • 10.4.3. Gene Expression Analysis

11. Cancer/Tumor Profiling Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Clinical Laboratories
    • 11.1.2. Reference Laboratories
  • 11.2. Hospitals Clinics
    • 11.2.1. Oncology Departments
    • 11.2.2. Pathology Labs
  • 11.3. Pharma & Biopharma Companies
    • 11.3.1. Clinical Trial Units
    • 11.3.2. Companion Diagnostic Services
    • 11.3.3. Drug Development Divisions
  • 11.4. Research & Academic Institutes
    • 11.4.1. Biotech Research Centers
    • 11.4.2. Government Research Institutes
    • 11.4.3. University Research Labs

12. Cancer/Tumor Profiling Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer/Tumor Profiling Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer/Tumor Profiling Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer/Tumor Profiling Market

16. China Cancer/Tumor Profiling Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Caris Life Sciences, Inc.
  • 17.8. F. Hoffmann-La Roche Ltd
  • 17.9. Guardant Health, Inc.
  • 17.10. Illumina, Inc.
  • 17.11. Natera, Inc.
  • 17.12. NeoGenomics, Inc.
  • 17.13. PerkinElmer, Inc.
  • 17.14. QIAGEN N.V.
  • 17.15. Sysmex Corporation
  • 17.16. Tempus Labs, Inc.
  • 17.17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EPIGENETIC PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EPIGENETIC PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EPIGENETIC PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MSI TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MSI TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MSI TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MUTATION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MUTATION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MOLECULAR SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MOLECULAR SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MOLECULAR SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PATHOLOGY LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PATHOLOGY LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL TRIAL UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL TRIAL UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL TRIAL UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPANION DIAGNOSTIC SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPANION DIAGNOSTIC SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPANION DIAGNOSTIC SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DRUG DEVELOPMENT DIVISIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DRUG DEVELOPMENT DIVISIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DRUG DEVELOPMENT DIVISIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOTECH RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOTECH RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOTECH RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY UNIVERSITY RESEARCH LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY UNIVERSITY RESEARCH LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY UNIVERSITY RESEARCH LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 274. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2032 (USD MILLION)
  • TABLE 276. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 278. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 280. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 292. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 296. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2018-2032 (USD MILLION)
  • TABLE 298. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 300. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY HOSPITALS CLINICS, 2018-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA CANCER/TUMOR PRO